HEPATOCELLULAR CARCINOMA

This study is testing whether adding a PD-1 inhibitor drug after microwave ablation treatment can help prevent early-stage liver cancer from returning. Researchers want to see if this combination approach improves how long patients live without their cancer coming back. The study…

This study is testing a new treatment called RP2, which is a modified virus designed to attack cancer cells and boost the immune system. It is for people with advanced liver cancer or bile duct cancer that has continued to grow despite standard treatment. The goal is to see if RP…

This early-phase study is testing the safety of a new personalized treatment for advanced cancers, primarily liver cancer. Doctors take a patient's own immune cells, modify them in a lab to better target cancer, and infuse them back. The main goal is to see if this approach is sa…

This early-stage study is testing whether genetically modified immune cells can fight solid tumors in children and young adults. Researchers collect patients' own immune cells, modify them to better recognize and attack cancer cells, then infuse them back into the body. The study…

This Phase 3 trial is testing whether a drug called ADI-PEG 20 can help people with advanced liver cancer that cannot be surgically removed. The study will compare the drug against a placebo in 300 participants who have high levels of a natural substance called arginine in their …

This is the first study in people to test a new drug, BAY 3547926, for advanced liver cancer (hepatocellular carcinoma). The drug works by delivering a tiny amount of radiation directly to cancer cells to try to shrink tumors. The main goals are to find a safe dose and see how we…

This study is testing a specialized type of radiation called carbon ion radiotherapy for people with liver cancer that has come back or didn't fully respond to a previous treatment called TARE. The goal is to see if this precise radiation can control the tumor while causing fewer…

This study is testing whether adding an oral medication called memantine to two standard cancer drugs (atezolizumab and bevacizumab) is more effective for treating advanced liver cancer that cannot be removed by surgery. It will enroll about 19 adults with newly diagnosed, untrea…

This is the first study in humans testing whether ZW251, a new targeted cancer drug, is safe and can help people with advanced liver cancer and other solid tumors. Researchers will give the drug to about 100 participants to find the right dose and see if it shrinks tumors. The ma…

This is the first study in people testing a new cancer drug called MGC026. It aims to find a safe dose and see if the drug can help shrink tumors in adults with advanced solid tumors that have not responded to other treatments. The study will also check how the drug moves through…

This program provides access to an investigational drug called ulixertinib for patients with advanced cancers that have specific genetic changes (MAPK pathway mutations). It is for people who have run out of other treatment options. The drug aims to control the cancer's growth, e…

This study is testing a new oral medication called Alintegimod, given alongside the immunotherapy drugs ipilimumab and nivolumab. It aims to see if this combination is safe and can help control advanced cancers that have spread or returned after other treatments. The study will e…

This study is testing a new two-step approach for a common type of liver cancer. First, patients receive a short, intense course of focused radiation. Then, they have surgery to remove the tumor. The main goal is to see if this combined approach is safe and doesn't cause delays o…

This study is testing a new three-drug combination for advanced liver cancer. The main goal is to find safe dose ranges and see if using artificial intelligence to personalize each patient's dose can improve results and reduce side effects. It will enroll about 12 adults whose ca…

This study is testing if a new combination treatment works better for people with advanced liver cancer that has spread heavily within the liver. It compares two immunotherapy drugs, with or without a targeted chemotherapy infusion delivered directly to the liver. The goal is to …

This study is testing whether a drug called memantine, commonly used for Alzheimer's disease, can help control advanced liver cancer in patients who also have severe liver scarring (cirrhosis) and are too sick for standard chemotherapy. It will measure if the cancer stops growing…

This study is testing whether the drug enfortumab vedotin can help control advanced colorectal cancer or liver cancer that has spread or cannot be surgically removed. It is for adults whose cancer has continued to grow despite trying standard treatments. The main goal is to see i…

This study is testing a new treatment plan to stop liver cancer from coming back after surgery. Patients with high-risk liver cancer will receive a combination of targeted chemotherapy and an immunotherapy drug before their operation, followed by more immunotherapy after surgery.…

This study is testing whether combining a cancer drug (regorafenib) with a targeted radiation treatment (Y-90 radioembolization) can better control advanced liver cancer that cannot be removed by surgery. It will enroll 30 adults who have not had prior drug treatment for their ca…

This study is testing if the drug cabozantinib can help control liver cancer that has come back in people who previously had a liver transplant. The drug works by blocking proteins that help cancer tumors grow. About 20 participants will take the drug until it stops working or si…

This study is testing whether a single injection called IP-001 can help prevent liver cancer from returning after the main tumor has been removed or destroyed. It is for patients who have had successful surgery or a heat-based treatment but are at a higher risk of the cancer comi…

This study is testing whether adding a new oral drug called CVM-1118 to an existing immunotherapy (nivolumab) can better control advanced liver cancer that cannot be surgically removed. It is for about 95 adults whose cancer has progressed after standard treatments. The main goal…

This early-stage study is testing a new type of personalized cell therapy for adults with advanced solid tumors that have a specific marker called GPC3. Doctors take a patient's own immune cells, genetically modify them in a lab to better recognize and attack cancer, and then inf…

This early-stage study is testing a new combination treatment for advanced liver cancer that cannot be cured by surgery. It combines precise, high-dose radiation (SBRT) with two immunotherapy drugs (atezolizumab and bevacizumab) to see if the body's immune system can better fight…

This study is testing a three-part treatment given before surgery for a serious form of liver cancer that has grown into a major blood vessel. The goal is to see if combining targeted radiation, an immunotherapy drug (camrelizumab), and a drug that blocks tumor blood supply (apat…

This study is testing whether combining two drugs, Envafolimab and Lenvatinib, can help control advanced cancers like lung, kidney, and liver cancer that have progressed after standard treatments. The goal is to see if this combination is safe and can shrink tumors better than cu…

This study is testing whether a three-part treatment can help people with liver cancer become eligible for a liver transplant. It combines a targeted radiation treatment (Y-90) with two drugs (atezolizumab and bevacizumab) to try to shrink or control tumors. The goal is to either…

This study is testing a two-part treatment for advanced liver cancer. Doctors deliver chemotherapy directly to the liver tumor and add a temporary blocking agent (lipiodol) to cut off its blood supply. The goal is to see if this combination is more effective at shrinking tumors a…

This study is testing a new oral drug called TTI-101 for people with advanced liver cancer that cannot be removed by surgery. The main goals are to find a safe dose and see if the drug, given alone or with other cancer therapies, can help control the cancer. It is for adults whos…

This study is testing a new three-drug combination (casdozokitug, toripalimab, and bevacizumab) for people with advanced liver cancer that cannot be removed by surgery. The main goals are to find a safe and effective dose and to see how well the treatment shrinks tumors. It will …

This study monitors the safety and effectiveness of two already-approved liver cancer drugs (Imjudo and Imfinzi) in real-world medical practice in Korea. It will follow 246 patients who are receiving these drugs as part of their standard cancer treatment. The goal is to collect i…

This study is testing a new drug called AK112, given alone or in combination with other treatments, for people with advanced liver cancer. The first part checks safety and finds the right dose, while the second part compares AK112 treatments to current standard care. Researchers …

This study is testing a new experimental drug called AZD9793 in adults with advanced liver cancer that has spread or cannot be removed by surgery. The main goals are to find a safe dose and see if the treatment can shrink tumors. Researchers will give the drug to about 304 partic…

This early-stage trial is testing a new personalized treatment called ECT204 T-cell therapy for adults with advanced liver cancer (hepatocellular carcinoma) that has not responded to at least two other treatments. Doctors collect a patient's own immune cells, genetically modify t…

This study is testing a precise form of radiation therapy (SBRT) to control liver cancer in patients waiting for a liver transplant. It is for people who cannot receive the standard bridge treatments like ablation or chemoembolization. The goal is to see if this radiation can saf…

This study is testing whether adding a third drug (lenvatinib) to a two-drug immunotherapy combination (durvalumab + tremelimumab) works better for controlling advanced liver cancer that cannot be removed by surgery. It will involve about 140 adults who have not yet received drug…

This study is testing whether adding an experimental cancer vaccine (UCPVax) to a standard immunotherapy drug combination (atezolizumab and bevacizumab) can better control advanced liver cancer that cannot be removed by surgery. It will involve about 105 adults with this type of …

This is the first study in humans testing a new drug called MT-303 for advanced liver cancer that has spread or cannot be removed by surgery. Researchers will give the drug alone or combined with standard cancer medications to 70 participants to find the safest dose and see if it…

This study is testing if a common steroid called prednisone can protect the liver from damage during radiation treatment for liver cancer. Twenty patients at high risk for liver inflammation will take prednisone for a few days before and during their radiation therapy. Researcher…

This study is testing whether adding a precise, high-dose radiation treatment (SBRT) to standard drug therapy helps people with advanced liver cancer live longer than using drug therapy alone. About 184 participants will be randomly assigned to receive either the combination trea…

This study is testing a new, personalized approach to find effective treatments for patients with advanced liver or colorectal cancer that has stopped responding to standard therapies. Doctors will grow miniature 3D models of a patient's own tumor in the lab to test how it respon…

This study is testing whether the time of day an immunotherapy drug called tislelizumab is given affects how well it works to prevent liver cancer from coming back after surgery. It will enroll 33 adults who have had surgery for high-risk liver cancer but show no signs of the dis…

This study aims to check the safety of two different drug treatments for people with advanced liver cancer that cannot be removed by surgery. It focuses on patients who also have significant liver damage (scarring) from cirrhosis. Researchers will test a two-drug combination and …

This study is testing whether adding a precise form of radiation, called carbon ion radiotherapy, to a standard two-drug treatment helps people with advanced liver cancer. It aims to see if this combination can control the cancer for longer and improve survival compared to the dr…

This is a first-in-human study to test the safety and find the right dose of a new drug called PF-08046054/SGN-PDL1V for people with advanced solid tumors. It will be tested alone and in combination with another cancer drug, pembrolizumab. The study is recruiting 714 participants…

This study is testing whether giving two drugs, sintilimab and bevacizumab, before surgery can help people with liver cancer that is more advanced but still removable. The goal is to shrink the tumor and, most importantly, lower the high chance of the cancer returning after the o…

This study is testing if adding a procedure called TACE after curative liver cancer surgery helps prevent the cancer from coming back. It will involve 442 patients who have had surgery but are at high risk of recurrence. Patients will be randomly assigned to either receive the TA…

This study is testing if a newer, ultrasound-guided endoscopic procedure is better than standard treatment at preventing dangerous variceal re-bleeding in people with liver cancer (HCC). It will enroll 84 patients who have recently had a bleeding episode controlled. The main goal…

This study is testing whether new immune-boosting drugs, given alone or with other cancer drugs, can help control advanced liver or bile duct cancer. It will enroll about 294 adults whose cancer has spread and is no longer responding to standard treatments. The main goals are to …

This study is testing a new drug called PF-08634404 to see if it is safe and effective for treating advanced liver cancer that cannot be removed by surgery. It will be given alone or combined with another drug (ipilimumab) to 138 adults who have not had other whole-body treatment…

This is the first study in people to test a new cancer drug called SIM0610. It aims to find a safe dose and see if it can shrink tumors in adults with advanced solid cancers that have stopped responding to standard treatments. The study will enroll 260 people with cancers like lu…

This large, late-stage trial is testing new drug combinations for people with advanced liver cancer that cannot be cured with surgery. It will compare two experimental combinations against a current standard treatment to see which helps patients live longer and control their canc…

This study is testing a personalized vaccine designed to prevent liver cancer from coming back after surgery. The vaccine is custom-made for each patient using their own tumor and immune cells, and is given alongside an immunotherapy drug called nivolumab. The goal is to see if t…

This study is testing a new three-drug combination for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if adding a new drug called zanzalintinib to two existing immunotherapy drugs helps control the cancer better. The study will first find …

This study is testing a new combination of four medicines for children and young adults (under 30) whose solid tumors have come back or haven't responded to standard treatments. The first part checks if the drug mix is safe and finds the right dose. The second part sees how well …

This study is testing if adding two immunotherapy drugs, atezolizumab and bevacizumab, to a standard heat treatment (radiofrequency ablation) can better prevent liver cancer from returning. It will involve 202 adults with early-stage liver cancer. The goal is to see if this combi…

This study is testing whether a combination of two immunotherapy drugs (tremelimumab and durvalumab) is safe and effective for people with advanced liver cancer who also have moderately impaired liver function, known as Child-Pugh B cirrhosis. It focuses on including patients fro…

This first-in-human study is testing an experimental cancer treatment called IDOV-Immune, which uses a modified virus designed to infect and destroy cancer cells while boosting the immune system. The trial aims to find the safest dose and check for early signs that the treatment …

This early-stage study is testing whether adding targeted radiation to two immunotherapy drugs is safe and tolerable for people with operable liver cancer. The goal is to shrink tumors before surgery to improve outcomes. About 20 participants will receive either the two drugs alo…

This study is testing whether giving a cancer immunotherapy treatment called nivolumab as an injection at home is a safe and practical alternative to receiving it at a clinic. It aims to see if home treatment reduces the burden of travel and improves quality of life for patients …

This early-stage study is testing a new type of cell therapy called C-CAR031 for people with advanced liver cancer that has not responded to standard treatments. Doctors will collect and modify a patient's own immune cells to better attack cancer, then infuse them back. The main …

This trial is testing whether combining two drugs, cabozantinib and durvalumab, is safe and effective for people with advanced cancers of the digestive system. It is for adults whose stomach, esophageal, liver, or colorectal cancer has progressed after standard treatments. The go…

This study is testing a combination of two types of drugs for adults with advanced liver cancer that cannot be removed by surgery. The goal is to see if using these drugs together is safe and can help control the cancer. One drug aims to starve the tumor by blocking its blood sup…

This study is testing whether drinking special nutritional supplements for a week before major liver surgery can help patients recover better. Researchers will compare 100 patients who receive these immune-boosting drinks to those who follow standard nutrition. The goal is to see…

This is the first human study of an experimental drug called JMT106 for people with advanced solid tumors, including certain lung and liver cancers. The main goal is to find a safe dose and see how the body handles the drug in about 200 participants who have run out of standard t…

This study is testing if adding a dietary supplement called beta-alanine to standard first-line immunotherapy helps people with advanced liver cancer. The main goal is to see if it reduces cancer-related fatigue and is safe to take. Researchers will also explore if this combinati…

This study is testing a combination of three medicines—durvalumab, tremelimumab, and lenvatinib—as the first treatment for people with advanced liver cancer that cannot be removed by surgery. The goal is to see if this three-drug approach can better control the cancer's growth an…

This study is testing a new type of personalized cell therapy called C-CAR031 for adults with advanced liver cancer that has come back or stopped responding to standard treatments. Doctors will take a patient's own immune cells, modify them in a lab to better target the cancer, a…

This study tests whether adding two localized liver treatments to an approved drug combination can better shrink advanced liver cancer. It will involve about 55 adults with liver cancer that cannot be surgically removed. The main goal is to see how many patients' tumors respond t…

This study aims to find a better way to check if liver cancer returns in patients who have been cancer-free for over two years. Researchers will compare a shorter, specialized MRI scan to the standard CT scan to see which is more effective at spotting new tumors early. The goal i…

This study is testing if a special type of ultrasound, called contrast-enhanced ultrasound (CEUS), can better check if a liver cancer treatment is working. It will compare CEUS to the standard CT or MRI scans that patients already get. The goal is to see if CEUS can give doctors …

This study is testing whether adding a quick, 10-minute MRI scan to the standard 6-month ultrasound check can help find liver cancer at its earliest, most treatable stage in people with cirrhosis who are at high risk. Researchers will compare the two approaches in about 944 patie…

This study is testing whether a new blood test can predict if liver cancer will come back after surgery. Researchers will measure tiny pieces of tumor DNA in the blood of 150 patients before and after their treatment. The goal is to see if this 'liquid biopsy' can provide an earl…

This study is testing a new type of imaging scan called PYLARIFY PET-CT. The goal is to see if it can more accurately detect when cancer has spread (metastasized) in patients with pancreatic, liver, or breast cancer. Researchers will compare the new scan's results to current stan…

This study is testing new, advanced ultrasound techniques to improve the detection and diagnosis of liver cancer. It aims to see if these new methods can find small tumors that standard ultrasound often misses, especially in patients at high risk. Finding cancer earlier is critic…

This study is testing if a faster, 20-minute MRI scan without dye is better than the standard ultrasound for finding liver cancer early in people with cirrhosis who are at high risk. Researchers will enroll 300 participants to receive both scans every six months for 30 months to …

This study is testing a new imaging substance called [18F]FAPI-74 to see if it can detect certain cancers better than current standard scans. It will involve 320 adults with one of 10 specific cancer types who are scheduled for treatment. Participants will receive both the new tr…

This study is testing a new blood test algorithm called Elecsys GAAD to see if it can help detect liver cancer earlier in people with liver cirrhosis. Researchers will enroll 600 patients with cirrhosis to compare this new test against current standard screening methods. The main…

This study is testing whether cancer patients prefer to receive their standard drug treatments at home instead of in a clinic. Researchers want to see if home-based care reduces the burden of travel and improves treatment satisfaction and quality of life for patients. A specializ…

This study asks cancer patients which way they prefer to receive their immunotherapy drugs: as a quick injection under the skin or through a longer IV infusion. Researchers will enroll 480 people with various advanced cancers to compare comfort, convenience, and quality of life b…

This study is testing whether a supplement made from Antrodia cinnamomea, a medicinal mushroom used in Taiwan, can help people with liver cancer feel better after a standard artery-blocking treatment called TACE. Researchers want to see if it reduces common side effects like pain…

This study aims to understand how chronic liver diseases, like hepatitis and fatty liver, are connected to other health problems a person might have. Researchers will look back at the medical records of up to 15,000 patients from Tzu Chi hospitals to see how these conditions affe…

This study aims to find out if measuring a specific protein in the blood (called GPC-3) can help doctors predict which patients with advanced liver cancer will respond best to a standard immunotherapy drug combination. Researchers will track 240 patients receiving the drugs atezo…

This research aims to understand the genetic and molecular causes of childhood liver cancers by collecting tissue samples from patients and their families. The study will analyze DNA and tumor tissue to create a better classification system based on biology rather than appearance…

This study aims to test two scoring systems (PLEASE and M10S20) to predict which patients with advanced chronic liver disease are most likely to develop liver failure or liver cancer. Researchers will follow 600 hospitalized patients, comparing a new risk-based monitoring schedul…

This study aims to use artificial intelligence (AI) to analyze standard CT scans from liver cancer patients. The AI will look at body composition, like muscle and organ health, to understand a patient's overall condition. The goal is to create a tool that helps doctors better pre…

This study aims to grow miniature versions of liver tumors in the lab using patient tissue samples. Researchers will test how these mini-tumors respond to different cancer drugs and study how gut bacteria might affect treatment success. The goal is to better understand what makes…

This study aims to understand why some liver cancer patients respond to immunotherapy while others do not. Researchers will collect blood, tissue, and health data from 500 adults with liver cancer who have had or will have immunotherapy. By analyzing this information over time, t…

This study aims to find out if measuring a protein called Galectin-3 in the blood can help predict how patients with certain cancers will respond to immunotherapy drugs (PD-1/PD-L1 inhibitors). Researchers will observe 300 adults with kidney, lung, liver, or bladder cancer who ar…

This study is monitoring patients for five years after they received an experimental cancer immunotherapy from Replimune. The goal is to check for any delayed side effects or safety issues that might appear long after treatment. About 50 patients with cancers like melanoma or liv…

This study aims to use artificial intelligence (AI) to make a minimally invasive liver cancer treatment called thermal ablation more effective and accessible. Researchers will collect data from 1500 patients to develop AI tools that help doctors better select patients, plan treat…

This study aims to find biological markers in the blood that can predict how well liver cancer patients respond to a specific immunotherapy combination (tremelimumab and durvalumab). Researchers will follow 120 patients with advanced liver cancer who are receiving this treatment …

This study aims to better understand how inherited changes in the BAP1 gene increase the risk for several types of cancer, including eye and skin melanoma, kidney cancer, and mesothelioma. Researchers will enroll 500 participants who have a personal or strong family history of th…

This study aims to understand how a hepatitis D treatment called bulevirtide affects gut bacteria and bile acids in patients. Researchers will follow 20 patients with hepatitis D and liver damage, collecting samples over 48 weeks to see how these gut factors change during treatme…

This study is testing if a special PET scan and a blood test can help doctors predict how well a radiation treatment will work for liver cancer. Researchers will enroll 60 patients who are scheduled to receive the standard radiation therapy. The goal is to see if these new tests …

This study aims to understand why people with lower incomes in Los Angeles County are more likely to be diagnosed with liver cancer at a late stage. Researchers will survey and interview about 730 newly diagnosed patients to learn about social barriers like transportation, housin…

This study tests whether a 'Teaching the Teachers' approach helps spread liver cancer diagnosis guidelines more widely. It involves training expert radiologists, who then teach the guidelines to other doctors. Researchers will track how often these guidelines are taught and used …

This study is testing a new way to collect blood for cancer detection. Researchers want to see if taking blood from a vein directly draining the cancer during a biopsy finds more tumor DNA than a standard blood draw from the arm. The goal is to improve the accuracy of blood tests…

This study aims to find biological markers in blood and tumor tissue that can predict how well patients with advanced liver cancer respond to immunotherapy. Researchers will collect samples from 50 patients before and during their treatment to analyze genetic and immune system ch…

This study is looking back at the medical records of 2000 people in China with liver cancer (hepatocellular carcinoma) who received treatments to try to shrink their tumors before possible surgery. The goal is to figure out which combinations of drugs and procedures work best for…